ArticleNPJ digital medicine2025
Harnessing machine learning for the development, validation, and prognostic evaluation of MASHRisk score: insights from a multicohort study.
Article in NPJ digital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Single-cell and machine learning-based neural regulation signature for prognosis prediction and immunotherapy response in lung adenocarcinoma.Translational oncology · 2026Article
- Construction of an explainable machine learning model based on SHAP for predicting cardiovascular mortality risk among American cancer survivors.Discover oncology · 2026Article
- The application of artificial intelligence in the intersection of metabolic dysfunction-associated steatotic liver disease and cardiovascular diseases.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Metabolic dysfunction-associated steatohepatitis (MASH) increases liver-related mortality risk more than tenfold, yet reliable predictive biomarkers remain scarce. This study developed the MASHRisk score, a blood-based non-invasive diagnostic tool integrating routine clinical and biochemical panels. Using ten machine learning algorithms, the score was derived from 218 participants and validated across multiple cohorts (n = 93, 96, and 26,256). The MASHRisk score demonstrated robust diagnostic performance with area under the receiver operating characteristic curve (AUC) values of 0.791, 0.793, 0.806, and 0.796 across training, validation, and test sets, respectively. It emerged as an independent predictor of MASH (p < 0.001) and outperformed existing indices including Fibrosis-4 (FIB-4), aspartate aminotransferase to Platelet Ratio Index (APRI), aspartate aminotransferase to alanine aminotransferase Ratio (AAR), and Non-Alcoholic Fatty Liver Disease Fibrosis Score (NFS). In a prognostic cohort of 390,574 individuals, high-risk participants showed significantly elevated hazard ratios (HR) for liver-related mortality (HR: 12.296), MASH (HR: 12.829), cirrhosis (HR: 8.863), hepatocellular carcinoma (HR: 9.278), atherosclerotic cardiovascular disease (ASCVD)-related mortality (HR: 2.303), and all-cause mortality (HR: 1.744) compared to low-risk individuals (all p < 0.001). The MASHRisk score represents a validated, user-friendly tool for early detection, risk stratification, and outcome prediction in MASH.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.